Results 141 to 150 of about 54,797 (163)

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study

Journal of the American Academy of Dermatology, 2016
Jon M Hanifin, Charles N Ellis, Ilona J Frieden   +2 more
exaly  

FR226807: a potent and selective phosphodiesterase type 5 inhibitor

European Journal of Pharmacology, 2001
Akira Nagashima, Tohru Ozaki, Jiro Seki   +2 more
exaly  

EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor

Neurological Research, 2009
Esra Okuyucu, Taskin Duman, Sadik Gorur   +2 more
exaly  

Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis

Multiple Sclerosis Journal, 2004
Yuji Nakatsuji, Hikoaki Fukaura, Seiji Kikuchi   +2 more
exaly  

Phosphodiesterase Inhibitors

2007
openaire   +2 more sources

Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction

Expert Opinion on Investigational Drugs, 2010
Ma Limin, Wayne J G Hellström
exaly  

Phosphodiesterase Inhibitors

2012
openaire   +1 more source

Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859

European Journal of Pharmacology, 2003
Yuhong Qiu, Sheela Bhattacharjee, Patricia Kraft   +2 more
exaly  

Olprinone: A Phosphodiesterase III Inhibitor with Positive Inotropic and Vasodilator Effects

Cardiovascular Drug Reviews, 2002
Katsufumi Mizushige, Hitoshi Suzuki
exaly  

Phosphodiesterase‐5 Inhibitors and Migraine

Headache: The Journal of Head and Face Pain, 2004
Evans, Randolph W, Kruuse, Christina Rostrup   +1 more
openaire   +3 more sources